Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RVMD with free AI briefings, catalyst countdowns, and dilution alerts.

RVMD · Revolution Medicines, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.2B Cash on Hand
31.3mo Cash Runway
6.4% Short Interest
$274.68 Analyst Target (24)
Follow RVMD by email Get an email when RVMD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RVMD, unsubscribe in one click. Privacy

📣 What RVMD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Daraxonrasib (RMC-6236)
FDA approved Aug 2026 · Rasonque
Pancreatic Cancer Phase 3 · NCT06625320 Active not recruiting
Zoldonrasib (RMC-9805) NSCLC Phase 3 · NCT07777822 Recruiting
Nab-paclitaxel Pancreatic Cancer Phase 3 · NCT06625320 Active not recruiting
Liposomal irinotecan Pancreatic Cancer Phase 3 · NCT06625320 Active not recruiting
Fluorouracil Pancreatic Cancer Phase 3 · NCT06625320 Active not recruiting
Irinotecan Pancreatic Cancer Phase 3 · NCT06625320 Active not recruiting
Vociprotafib (RMC-4630) Metastatic Neoplasm Phase 1/2 · NCT04418661 Terminated
Vopimetostat (TNG462) PDAC Phase 1/2 · NCT06922591 Recruiting
Elironrasib (RMC-6291) Non-Small Cell Lung Cancer, NSCLC Phase 1/2 · NCT06162221 Recruiting
mFOLFIRINOX regimen Colorectal Cancer Phase 1/2 · NCT06445062 Recruiting
Osimertinib Mesylate Solid Tumor Phase 1/2 · NCT03989115 Completed
FOLFIRI regimen Colorectal Cancer Phase 1/2 · NCT06445062 Recruiting
Ivonescimab Advanced Solid Tumors Phase 1/2 · NCT07397338 Recruiting
mFOLFIRINOX PDAC Phase 1/2 · NCT06922591 Recruiting
mFOLFOX6 regimen Colorectal Cancer Phase 1/2 · NCT06445062 Recruiting
KRAS G12V Inhibitor RMC-5127 Non-small Cell Lung Cancer (NSCLC) Phase 1 · NCT07349537 Recruiting

Also used in these trials (approved or third-party drugs, not RVMD's own candidates): Leucovorin, Pemetrexed Disodium, Pembrolizumab, Oxaliplatin, Gemcitabine Hydrochloride, Docetaxel Anhydrous, Carboplatin, Adagrasib, Sotorasib, Bevacizumab, Cobimetinib, Cisplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RVMD holds $4.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $401.5M/quarter from operations, an estimated runway of 31.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 32 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RVMD files for a raise →

👥 Who Owns RVMD

Insiders 1.6% Other 5%+ holders 6.7% Institutions (1021 holders) 91.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 15,402,103 7.12% 2026-09-30
Dapice Joshua J. 5%+ holder (13G) 14,596,149 6.75% 2025-12-31
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 13,564,149 6.27% 2026-06-30
Farallon Capital Management LLC Institution (13F) 13,418,796 6.20% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 12,201,395 5.64% 2026-06-30
Baker Bros. Advisors LP Institution (13G, 5%+) 11,443,357 5.29% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 10,999,044 5.09% 2026-09-30
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 10,736,145 4.96% 2026-06-30
Darwin Global Management, Ltd. Institution (13F) 10,629,822 4.91% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 8,157,073 3.77% 2026-09-30
Nextech Invest, Ltd. Institution (13F) 7,601,087 3.51% 2026-09-30
Paradigm Biocapital Advisors LP Institution (13F) 6,219,323 2.88% 2026-09-30

Share count 216,292,323 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-11
filed 2026-11-13
Borisy Alexis
Gift (G) 10,625 – 2,329,450
2026-11-11
filed 2026-11-13
Anders Jack
Option exercise (M) 19,850 $18.56 –
2026-11-11
filed 2026-11-13
Anders Jack
Option exercise (M) 15,900 $42.45 –
2026-11-11
filed 2026-11-13
Anders Jack
Sale (S) 9,889 $192.84 119,216
2026-11-11
filed 2026-11-13
Anders Jack
Sale (S) 9,486 $191.94 129,105

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full RVMD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RVMD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.